Environmental factors affecting IBD Have we made progress? Peter Laszlo Lakatos 1st Department of Medicine Semmelweis University Budapest Hungary

Similar documents
Environmental exposure: can we reduce risk?

Genetic and Environmental Risks for IBD

What is IBD and Why Me?

Genetics of Pediatric Inflammatory Bowel Disease

Inflammatory Bowel Disease A model for translational medicine. D P Jewell Professor Emeritus of Gastroenterology University of Oxford

Inflammatory Bowel Diseases (IBD) Clinical aspects Nitsan Maharshak M.D., IBD Center, Department of Gastroenterology and Liver Diseases Tel Aviv Soura

5/2/2018 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD

Predicting the natural history of IBD. Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium

PEDIATRIC INFLAMMATORY BOWEL DISEASE

Causes of IBD: The Role of Genetics and Microbes and the Epidemiology of IBD

Gut Microbiota and IBD. Vahedi. H M.D Associate Professor of Medicine DDRI

Disease behavior in adult patients- are there predictors for stricture or fistula formation?

Anti-TNF and cyclosporine are identical choices for severe ulcerative colitis refractory to steroid therapy CON Peter Laszlo LAKATOS Semmelweis

Crohn s Disease. Naturopathic Treatment Options

IBD high risk groups

Epidemiology of Inflammatory Bowel Disease and Overview of Pathogenesis

Can We Predict the Natural History of Ulcerative Colitis? Edward V Loftus, Jr, MD Professor of Medicine Mayo Clinic Rochester, Minnesota, USA

Epidemiology of Inflammatory Bowel Disease

Treatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10

Issues at Hand. Inflammatory Bowel Disease Paradigm. Diet changes the fecal microbiome. Experience with diet in IBD

Dietary Options for Inflammatory Bowel Disease

Factsheet - Risk factors for inflammatory bowel disease (IBD)

Zach Johnson---Masters Champion

Is there an anti-inflammatory diet in IBD?

Guided by Dr. Michal Amitai Head of Abdominal Imaging Department of Diagnostic Imaging Sheba Medical Center Sackler School of Medicine, Tel Aviv

The enteric microbiota: Implications for IBD. Eugene B. Chang, M.D. University of Chicago

Personalized Medicine in IBD: Where Are We in 2013

Personalized Medicine in IBD

Signal Transduction in Inflammatory Bowel Disease

Strategies for changing the course of Crohn s disease

Efficacy and Safety of Treatment for Pediatric IBD

Running head: CHRON'S DISEASE GENE-ENVIRONMENTAL INTERACTION 1

Towards Precision Medicine in Inflammatory Bowel Diseases

IBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD

Cancer Risk with IBD Therapies How to Discuss with your Patients?

Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy

Personalized Medicine. Selecting the Right First-line Biologic Agent. Gene Expression Profiles Crohn s Disease. The Right Treatment

Microbiome GI Disorders

Our microbiome: The role of vital gut bacteria, diet, nutrition and obesity

NON INVASIVE MONITORING OF MUCOSAL HEALING IN IBD. THE ROLE OF BOWEL ULTRASOUND. Fabrizio Parente

CCFA. Crohns Disease vs UC: What is the best treatment for me? November

ESPEN Congress Lisbon 2015 NUTRITIONAL ISSUES IN CROHN'S DISEASE. The clash of generations: children are not small adults S.

Understanding clinical aspects of Crohn s disease and ulcerative colitis: Implications for the basic scientist

Indications for use of Infliximab

Materials EXCLUSION CRITERIA INCLUSION CRITERIA

Communicating with the IBD Patient: How to convey risks and benefits

Mucosal healing: does it really matter?

Fructo-oligosaccharides in Crohn s disease: a prospective randomised double blind controlled trial

Dogma: no bacteria, no IBD!

Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease

IBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants

Chapter 2 Environmental Factors in the Epidemiology of Inflammatory Bowel Disease

Speaker Introduction

Slide 1. Slide 2 Learning outcomes. Slide 3. Year 1 MBChB Lecture 15 Introduction to the Gut Microbiota. The importance of microbiota

Genetics. Environment. You Are Only 10% Human. Pathogenesis of IBD. Advances in the Pathogenesis of IBD: Genetics Leads to Function IBD

Gut Microbiota in Inflammatory Bowel Disease

September 12, 2015 Millie D. Long MD, MPH, FACG

A Case of Inflammatory Bowel Disease

Accepted Manuscript. Does eradication of Helicobacter pylori cause inflammatory bowel disease? Johan Burisch, Tine Jess

4/17/2019 DISCLOSURES OBJECTIVES GI MICROBIOME & HEALTH: A REVIEW. Nancy C. Kois, MD, FCAP Contemporary Pathology Services. There are no disclosures

East west gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort

Optimizing Immunomodulators and

The future of IBD therapeutic research

IBD :- a new era of diagnostics and therapy Dr Martyn Dibb Consultant Luminal Gastroenterologist Royal Liverpool University Hospital

Crohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation?

Protocol for the management of acute severe ulcerative colitis in children

Gut Lung Axis Implication of the Gut Microbiota beyond its niche

1. Digestion of foods and absorption of nutrients takes place in stomach and small bowel in only 2-3 h.

Azienda Ospedaliera S. Camillo Forlanini. Unità Operativa di Gastroenterologia. Moscow June Cosimo Prantera

Presence of pseudopolyps in ulcerative colitis is associated with a higher risk for treatment escalation

Inflammatory Bowel Disease Cohort Studies in Korea: Present and Future

Implementation of disease and safety predictors during disease management in UC

Looking for Answers. IBD Research March 9, Dr. Benjamin Click, MD MS Associate Staff Cleveland Clinic

Page 1. Global trends in diet parallel IBD. Is there an anti-inflammatory diet for IBD? Patients want to know. Challenges in establishing causality

Agenda. Predictive markers in IBD. Management of ulcerative colitis. Management of Crohn s disease

Disclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists

Medical Management of Inflammatory Bowel Disease

UNDERSTANDING CROHN S DISEASE

Ali Keshavarzian MD Rush University Medical Center, Chicago, IL

Selective leucocyte trafficking inhibitors for treatment of IBD

Mono or Combination Therapy with. Individualized Approach

Azathioprine for Induction and Maintenance of Remission in Crohn s Disease

IBD Case Studies. David Rowbotham. Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology & Hepatology Auckland City Hospital

Microbiome in You: Optimizing Gut Bacteria for Better IBD Management

Probiotics in the ICU. Who could benefit? Nadia J van Rensburg RD(SA) Groote Schuur Hospital, Cape Town

Dr David Epstein Vincent Pallotti Hospital and University of Cape Town

Sarkis K Mazmanian, California Institute of Technology

Recent Advances in the Management of Refractory IBD

Achieving Success in Ulcerative Colitis: the Role of Infliximab

Nutrition as primary therapy in IBD. Dr Clare Donnellan Leeds General Infirmary

New treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital

Endpoints for Stopping Treatment in UC

COPYRIGHT. Inflammatory Bowel Disease What Every Clinician Needs to Know. Adam S. Cheifetz, MD. Director, Center for Inflammatory Bowel Disease

Infliximab (Remicade) for paediatric ulcerative colitis - second line

10/11/2010. Jonathan Braun, MD, PhD David Geffen School of Medicine at UCLA CCFA National Scientific Advisory Committee

Genetic Susceptibility. Objectives. What Causes IBD? Inflammatory Bowel Disease

Optimizing Management using CRP, Fecal Calprotectin and Ferritin. Peter Laszlo Lakatos 1st Department of Medicine Semmelweis University Budapest

Selby Inflamm Bowel Dis. 2008:14:

Fibrotic complications of inflammatory bowel disease

Challenges in IBD: The Post-Op IBD Patient: Preventing Pouchitis & Recurrence

Transcription:

Environmental factors affecting IBD Have we made progress? Peter Laszlo Lakatos 1st Department of Medicine Semmelweis University Budapest Hungary

Environmental factors in IBD Are associated with disease susceptibility? Predicting disease phenotype? During the course of the disease, are they of any value in predicting relapse? short-long term prognosis and risk for complications?

IBD a complex phenotype

Environmental factors in IBD flora stress smoking drugs (OC, NSAID) appendectomy IBD infections (measles, mycobacterium, pharyngitis, tonsillitis,) diet hygiene (refined sugar, fat, fast food, corn flakes, chocolate, cocacola, toothpaste)

Disease susceptibility

Diet? Evidence suggesting a relationship between sugars and onset of Crohn's disease was inconsistent and subject to important methodological limitations. There was a clear lack of distinction between reporting of current, as opposed to, retrospective intakes. There appeared to be no clinical advantage to the use of reduced sugar diets in Crohn's disease treatment Riordan AM Eur J Clin Nutr 1998;52:229-38.

Developed hygiene? Bernstein CN Am J GE 2006

Developed hygiene? Bernstein CN Am J GE 2006

Developed hygiene? OR for IBD 95%CI male gender 1.44 1.24-1.67 urban environment 1.38 1.02-1.78 number of siblings (1 vs 5 or more) higher birth order (5 or higher vs 1) 2.63 1.49-4.62 2.35 1.47-3.77 Klement E Am J GE 2008

Baron S Gut 2005 Developed hygiene?

Vaccination? Davis RL Arch Ped Adolesc Med 2001

Drugs, oral contraceptive use Bernstein CN Am J GE 2006

Oral contraceptive use OR CD : 1.44, OR CD : 1.51, (14 studies) 95%CI: 1.12-1.86 95%CI: 1.17-1.96 OR UC : 1.29, 95%CI: 0.94-1.77 Godet PG Gut 1995 Cornish JA Am J GE 2008

Appendectomy and risk of UC Rate of appendectomy in UC: 1/174 (0.6%) Rate of appendecytomy in controls: 41/161 (25.4%) OR: 59.1 (95% CI, 18-189) Rutgeerts NEJM 1994 Koutrobakis IBD 2002

Life events Lerebours E IBD 2007

Smoking

current vs never smoking 1.76 95%CI: 1.40-2.22 P<0.001 former vs never smoking 1.30 95%CI: 0.97-1.76 P=0.08 Mahid SS Mayo Clin Proc 2006

current vs never smoking 0.58 95%CI: 0.45-0.75 P<0.001 former vs never smoking 1.79 95%CI: 1.37-2.34 P<0.001 Mahid SS Mayo Clin Proc 2006

Passive childhood smoking Mahid SS IBD 2007

Is it infectious? Virus, bacteria or worms?

Dysbiosis in Crohn s disease? Faecal flora Bacteroides vulgatus Eubacteria Peptostreptococci Coprococci E.coli Bifidobacteria Lactobacilli

Mucosa associated bacteria are common in Crohn s disease 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% n = Asymptomatic controls Self-limiting colitis Intermediate colitis UC 40 28 104 119 CD 54 In 40% CD patients > 10 000 cfu/ml 0 <1000 cfu/μl 1000 <10000 cfu/μl 10000 <50000 cfu/μl >50000 cfu/μl Swidzsinski et al. Gastroenterology 2002

Cold chain is it a hypothesis? Epidemiological data allow assessment of familial environmental risk factors related to western lifestyle, diet, bacteria, and domestic hygiene. All findings point to refrigeration as a potential risk factor for Crohn s disease. Furthermore, cold-chain development paralleled the outbreak of Crohn s disease during the 20th century. The cold chain hypothesis suggests that psychrotrophic bacteria such as Yersinia spp and Listeria spp contribute to the disease. Hugot JP Lancet 2003

History of genetic research in IBD 1980 IBD is a (poly)genic and multifactorial disorder 1990 Genome-wide Linkage Scans Identification of susceptibility regions in CD Scepticism!!! 2001 NOD2/CARD15 CD becomes example of Success story Innate Immunity and Pattern Recognition Receptors Common pathways between inflammatory diseases 2006 Genome-wide Association Scans ATG16L1, IRGM, 24

Pattern recognition receptors (PRRs) Important role in innate immunity Recognition and response against Gramnegative bacteria Extracellular membrane bound, Toll Like Receptors (TLR) Intracellular in the cytosol, NOD2/CARD15 Some mutations predispose to bacterial infections, others to immune mediated diseases

Mucosa associated bacteria are common in Crohn s disease Barnich N World J GE 2007

Mucosa associated bacteria are common in Crohn s disease Darfeuille-Michaud A Gastroenterology 2004

But bacterial profile is not different between ulcerated and normal mucose in Crohn s disease dominant microbiotas do not differ qualitatively between ulcerated and nonulcerated mucosae. Biodiversity remains high in ulcerated mucosa. Vasquez N IBD 2007 Seksik J Clin Microbiol 2005

Trichuris suis in the treatment of IBD Summers RW Gut 2005 29 CD and 54 adult patients 2500 Trichuris suis ova/placebo every 2-3 w. for 12 w. Primary endpoint: CDAI<150 at week 24 improvement of UCDAI to 4 at 12 weeks Summers RW GE 2005

Predicting disease phenotype/disease course?

Indolent course Crohn s disease active 8% 48% inactive 44% D sis 1 2 3 4 5 6 7 8 Years after diagnosis Munkholm P, et al. Scand J Gastroenterol 1995:30:699 706

Aggressive course Crohn s disease active p <0.001 45% 50% inactive D sis 1 2 3 4 5 6 7 8 Years after diagnosis 5% Munkholm P, et al. Scand J Gastroenterol 1995:30:699 706

Is diet predicting the relapse rate in UC? Jowett SL Gut 2004

Is diet predicting the relapse rate in UC? Jowett SL Gut 2004

Is education level associated with time to relapse in UC? Hoie O Am J GE 2007

Stress

Is stress associated with disease course in IBD?

Is stress associated with disease course in CD? Bitton Gut 2008

Is stress associated with disease course in CD? Bitton Gut 2008

Smoking is associated with probability of flares in CD Cosnes J Gastroenterology 2001

Smoking and disease phenotype in CD % without stricture % without complicated disease Aldhous M. Am J GE 2007

Association between smoking, azathioprine/biological use and need for surgery in patients with Crohn`s disease 1,0 0,8 no IM / no smoking IM / no smoking no IM / smoking IM / smoking censored censored censored censored Survival without surgery 0,6 0,4 0,2 0,0 0,00 50,00 100,00 150,00 200,00 250,00 300,00 follow-up (months) plogrank<0.001, pbreslow<0.001 Szamosi T ECCO 2009

Summary of cox model: factors affecting time to first surgery Gender 0.671 Disease location 0.017 p Hazard Ratio 95%CI L1 0.865 1.04 0.70-1.53 L2 0.013 0.58 0.38-0.89 L3 Disease behavior <0.001 reference B1 <0.001 0.28 0.19-0.42 B2 0.09 0.70 0.46-1.06 B3 Smoking / Azathioprine-biological use <0.001 reference noaza-biological/no smoking 0.004 2.20 1.28-3.78 AZA-biological/no smoking 0.75 1.10 0.61-1.99 noaza-biological/smoking <0.001 3.19 1.86-5.47 AZA-biological/ smoking reference Szamosi T ECCO 2009

Smoking and disease phenotype in UC Aldhous M. Am J GE 2007

Association between smoking and colectomy in UC OR: 0.57 (95%CI: 0.38-0.85) Cosnes J Best Pract Res Clin GE 2004

Association between smoking and colectomy in UC 1,0 0,8 Survival without colectomy 0,6 0,4 0,2 0,0 no-smoking smoking censored censored 0,00 100,00 200,00 300,00 400,00 Szamosi T ECCO 2009 follow-up (months) plogrank=0.042, pbreslow=0.08

Appendectomy and disease course in UC Cosnes J Gut 2002

Environmental factors in IBD Disease susceptibilty: Conclusions Evidence supports the association between early life hygene, some dietary factors, smoking, appendectomy and oral contraceptive use (in females) and the development of IBD The role for dysbiosis or a specific infectious agent in the disease susceptibility is controversial Prediction of disease phenotype&course: Smoking is associated with relapse rate, change in disease behavior /extent and risk for surgery/colectomy Appendectomy seems to be preventive against colectomy Studies indicate that chronic stress, adverse life events, and avoidance coping can cause relapse in patients with IBD.